Tissue Engineering: Muscling in on the third dimension

  1. Mohsen Afshar Bakooshli
  2. Penney M Gilbert  Is a corresponding author
  1. University of Toronto, Canada

When building a house, ‘framing’ involves fitting together wooden or steel supports to give the house shape and to establish the dimensions of the space within it. The extracellular matrix—a dense web of proteins—serves a similar scaffolding role for tissues in the body. And having height, width and depth also really matters when it comes to tissues.

In the laboratory it is common to grow cells in a single two-dimensional layer on a plastic culture dish. This strategy has expanded our understanding of cells, but has often failed to lead to new therapies to treat the diseases and disorders that can afflict our tissues. In contrast, three-dimensional culture models of human skin, lung, cardiac tissue and liver faithfully mimic the responses of living tissue, and can be used to predict how these tissues might respond to potential therapies (Bhatia and Ingber, 2014). This is because being three-dimensional provides tissue with stability, acts as a scaffold for repair, and even seems to be involved in the progression of certain diseases (Pampaloni et al., 2007; Lancaster and Knoblich, 2014). It is not a surprise that there is a push within the tissue-engineering community to establish three-dimensional culture models of each and every human tissue.

Skeletal muscle is the most abundant tissue in the human body and is needed for moving limbs, blinking, swallowing, breathing and maintaining a constant body temperature. It is composed of many muscle cells that are aligned with one another and embedded within an extracellular matrix scaffold. Human muscle cells form as a result of many single cells fusing with one another to create a single long cylinder; this process was first recreated in two-dimensional culture dishes in the early 1980s (Blau and Webster, 1981). However, skeletal muscle contracts in response to electrical signals from the brain, and it has been notoriously difficult to grow human muscle fibers that have this property.

Now, in eLife, Nenad Bursac of Duke University and colleagues—including Lauran Madden as first author—report the first three-dimensional culture model of human skeletal muscle that responds to electrical and biochemical stimulation just like the real thing (Madden et al., 2015). First, Bursac, Madden and co-workers placed human muscle cells (which had been collected from biopsies of patients) in a two-dimensional culture dish and allowed them to undergo many rounds of cell division (Figure 1). They then mixed the cells into a protein-rich scaffold and transferred the mixture into a custom-made silicone rubber mold where it formed a soft porous gel (similar to jello [US] or jelly [UK]). A nylon frame included in the mold provided two attachment points for the gel, mimicking the sites where skeletal muscle attaches to bone via tendons. Within just two weeks, the cells had fused together to form long aligned muscle fibers. What's more, these muscle fibers could twitch and contract!

Bioengineered skeletal muscle that responds like human muscle tissue.

In the early 1980s scientists figured out how to grow muscle fibers from single cells (shown in red) in a two-dimensional plastic culture dish. However, it was necessary to expose the 2D cell culture (left) to a complex mixture of molecules to make it responsive to electrical stimulation. Madden et al. have now overcome this long-standing challenge; by using a custom three-dimensional culture device (right) and with just the right protein-rich scaffold (in yellow), they generated muscle fibers that respond to electrical and biochemical cues just like normal skeletal muscle tissue.

Prior attempts by other researchers using similar devices to mimic tendons had failed to contract in response to electrical stimulation (Powell et al., 2002; Chiron et al., 2012). The secret to success seems to be in the list of ingredients used to make the protein-rich scaffold. Most laboratories had previously used collagen, a protein that is abundant in skeletal muscle. However, Madden et al. used fibrin—a product of blood clotting found in skeletal muscle undergoing repair—and found that it worked better. Fibrin had previously been shown to also be the best choice for engineering three-dimensional muscle from mouse muscle cells (Hinds et al., 2011).

Madden et al. went on to show that, when stimulated electrically or chemically, the engineered skeletal muscle responds much like normal tissue: first it releases calcium ions (Ebashi and Endo, 1968) and then it starts twitching. Furthermore, three classes of pharmaceutical drugs had similar effects on the engineered muscle as they do on normal muscle tissue in clinical settings. These results validate the potential application of the engineered skeletal muscle as a preclinical platform for drug testing.

Skeletal muscle has an amazing capacity for repair due to the presence of a small population of stem cells residing within the tissue (Mauro, 1961). However, muscle mass and function can be lost as result of degenerative conditions, like aging, and genetic conditions, such as Duchenne muscular dystrophy. The availability of a three-dimensional model of human skeletal muscle provides hope for the identification of new drugs that improve muscle strength in a diverse range of clinical settings. Moreover, it opens the door to the possibility of creating muscle tissue in a dish from a patient's own cells and then using this model to identify the most effective treatment for the patient's condition: so-called skeletal muscle personalized medicine.

With every scientific advance come new challenges. It is still unclear whether the culture system developed by Madden et al. is suitable for modeling disorders such as Duchenne muscular dystrophy. Furthermore, for pharmaceutical companies to switch to a three-dimensional tissue model, the new model must first uncover important biological findings that are obscured in standard two-dimensional cultures. And in order to integrate the new culture device with high-throughput drug screening platforms, it will be necessary to make it smaller, while also establishing simple, cost-effective metrics that can rapidly assess health of the tissue. Regardless, the advance by Bursac, Madden and co-workers has pushed the field one step closer to achieving the goal of maintaining muscle strength and health throughout life.

References

    1. Blau HM
    2. Webster C
    (1981) Isolation and characterization of human muscle cells
    Proceedings of the National Academy of Sciences of USA 78:5623–5627.
    https://doi.org/10.1073/pnas.78.9.5623
    1. Ebashi S
    2. Endo M
    (1968) Calcium and muscle contraction
    Progress in Biophysics and Molecular Biology 18:123–183.
    https://doi.org/10.1016/0079-6107(68)90023-0
    1. Mauro A
    (1961) Satellite cell of skeletal muscle fibers
    Journal of Biophysical and Biochemical Cytology 9:493–495.
    https://doi.org/10.1083/jcb.9.2.493

Article and author information

Author details

  1. Mohsen Afshar Bakooshli

    Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada
    Competing interests
    The authors declare that no competing interests exist.
  2. Penney M Gilbert

    Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada
    For correspondence
    Penney.Gilbert@utoronto.ca
    Competing interests
    The authors declare that no competing interests exist.

Publication history

  1. Version of Record published:

Copyright

© 2015, Afshar Bakooshli and Gilbert

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,028
    views
  • 217
    downloads
  • 3
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mohsen Afshar Bakooshli
  2. Penney M Gilbert
(2015)
Tissue Engineering: Muscling in on the third dimension
eLife 4:e06430.
https://doi.org/10.7554/eLife.06430

Further reading

    1. Stem Cells and Regenerative Medicine
    Shiyu Zhang, Min Zhou ... Wei Zuo
    Research Article

    Background:

    In idiopathic pulmonary fibrosis (IPF) patients, alveolar architectures are lost and gas transfer function would decline, which cannot be rescued by conventional anti-fibrotic therapy. P63+ lung basal progenitor cells are reported to have potential to repair damaged lung epithelium in animal models, which need further investigation in clinical trials.

    Methods:

    We cloned and expanded P63+ progenitor cells from IPF patients to manufacture cell product REGEND001, which were further characterized by morphology and single-cell transcriptomic analysis. Subsequently, an open-label, dose-escalation autologous progenitor cell transplantation clinical trial was conducted. We treated 12 patients with ascending doses of cells: 0.6x, 1x, 2x and 3.3x106 cells/kg bodyweight. The primary outcome was the incidence and severity of cell therapy-related adverse events (AEs); secondary outcome included other safety and efficacy evaluations.

    Results:

    P63+ basal progenitor cell was safe and tolerated at all doses, with no dose-limiting toxicity or cell therapy-related severe adverse events observed. Patients in three higher dose groups showed significant improvement of lung gas transfer function as well as exercise ability. Resolution of honeycomb lesion was observed in patients of higher dose groups.

    Conclusions:

    REGEND001 has high safety profile and meanwhile encourages further efficacy exploration in IPF patients.

    Funding:

    National High Level Hospital Clinical Research Funding (2022-PUMCH-B-108), National Key Research and Development Plan (2024YFA1108900, 2024YFA1108500), Jiangsu Province Science and Technology Special Project Funding (BE2023727), National Biopharmaceutical Technology Research Project Funding (NCTIB2023XB01011), Non-profit Central Research Institute Fund of Chinese Academy of Medical Science (2020-PT320-005), and Regend Therapeutics.

    Clinical trial number:

    Chinese clinical trial registry: CTR20210349.

    1. Neuroscience
    2. Stem Cells and Regenerative Medicine
    Ana Catarina Costa, Blanca R Murillo ... Monica M Sousa
    Research Article

    Sensory dorsal root ganglion (DRG) neurons have a unique pseudo-unipolar morphology in which a stem axon bifurcates into a peripheral and a central axon, with different regenerative abilities. Whereas peripheral DRG axons regenerate, central axons are unable to regrow. Central axon regeneration can however be elicited by a prior conditioning lesion to the peripheral axon. How DRG axon asymmetry is established remains unknown. Here we developed a rodent in vitro system replicating DRG pseudo-unipolarization and asymmetric axon regeneration. Using this model, we observed that from early development, central DRG axons have a higher density of growing microtubules. This asymmetry was also present in vivo and was abolished by a conditioning lesion that decreased microtubule polymerization of central DRG axons. An axon-specific microtubule-associated protein (MAP) signature, including the severases spastin and katanin and the microtubule regulators CRMP5 and tau, was found and shown to adapt upon conditioning lesion. Supporting its significance, interfering with the DRG MAP signature either in vitro or in vivo readily abolished central-peripheral asymmetries in microtubule dynamics and regenerative ability. In summary, our data unveil that axon-specific microtubule regulation drives asymmetric regeneration of sensory neuron axons.